Aflac stock faces key test on benefit ratios in Q3 report

Aflac is set to release its third-quarter 2026 results after the U.S. market closes on Wednesday, November 4. The earnings preview by Earnings Whispers, published October 27, puts the focus on whether recent pressure on underwriting margins proves temporary or becomes a broader earnings issue.

Aflac stock traded at 111.50 euros on Lang & Schwarz at 13:33 CET on Wednesday, November 4, 2026. The quote is a pre-release market indication, while the company is scheduled to host its earnings webcast on Thursday, November 5.

Benefit ratios set the tone

The U.S. benefit ratio rose to 49.5% in the second quarter from 47.2% in the first quarter, with higher group disability claims contributing to the increase. Earnings Whispers said a retreat toward the earlier level would support the view that the deterioration was temporary, while another reading near 50% would raise tougher questions about pricing and underwriting in the group business.

Japan is another key test. Management had moved its full-year Japan benefit-ratio outlook toward the upper end of a 60% to 63% range, citing a shift in lapses from older policies to newer policies. A third-quarter result above that range would point to greater pressure on policy persistency than previously expected.

Growth and capital remain in focus

The preview also highlights Aflac's U.S. net earned premium outlook, which management had reduced to just below its earlier 3% to 6% range. Investors will therefore look for evidence that group, dental and vision sales are translating into earned premium growth.

In Japan, sales fell about 6% in the prior quarter against a difficult comparison with a major product launch. Management had continued to describe its roughly 80 billion yen full-year sales goal as achievable, although the preview characterized the target as demanding.

Aflac's capital and investment-income story provides a counterweight. A 4.8 billion U.S. dollar portfolio switch was expected to add more than 50 million U.S. dollars in annual net investment income, while expanded reinsurance capacity and external transactions could affect the market's assessment of capital generation.

For investors, the report's significance lies in the balance between those capital benefits and the insurance operation's claims and premium trends. A stable benefit-ratio picture could reinforce the defensive case for the insurer; renewed deterioration would make buybacks and investment gains less persuasive as offsets.

For the real-time quote of Aflac stock, investors should distinguish the pre-release indication from the company's results and management commentary due after the close.

Broader U.S. equity-market conditions will shape how investors assess insurers and other defensive financial stocks alongside Aflac.

More news and analyses on Aflac stock.